NASDAQ$ACET
Adicet Bio Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Adicet Bio reported financial results for Q4 2023 and full year, highlighting progress in clinical pipeline expansion into autoimmune diseases and advancements in ADI-001 and ADI-270 development.
Adicet Bio reported a net loss of $29.5 million for the fourth quarter of 2023, with R&D expenses at $24.8 million and G&A expenses at $6.8 million. The company highlighted the FDA clearance for ADI-001 in lupus nephritis and progress in advancing ADI-270 preclinical development. They extended their projected cash runway into 2H 2026.
- FDA cleared IND application for ADI-001 in lupus nephritis, with Phase 1 study initiation expected in 2Q 2024.
- Advanced ADI-270 preclinical development in solid tumors, remaining on track to file IND in renal cell carcinoma in 2Q 2024.
- Presented persistence and pharmacodynamic data from ADI-001 Phase 1 study at ASH Annual Meeting.
- Extended projected cash runway into the second half of 2026 following a successful capital raise and ATM program.
Headline financials
Revenue & EPS history
Adicet Bio · Revenue · Quarterly
$12.9M
Forward guidance
Adicet Bio anticipates several milestones, including initiating a Phase 1 study for ADI-001 in lupus nephritis in 2Q 2024 and filing an IND for ADI-270 in renal cell carcinoma in 2Q 2024. Preliminary clinical data for ADI-001 in lupus nephritis is expected in Q4 2024 or Q1 2025.
Tailwinds
- Initiate Phase 1 study of ADI-001 in lupus nephritis in 2Q 2024.
- File IND for ADI-270 in renal cell carcinoma in 2Q 2024.
- Provide clinical update on ADI-001 in MCL patients in the second half of 2024.
- Provide clinical data from Phase 1 study of ADI-270 in the first half of 2025.
- Expand ADI-001 development into additional autoimmune indications.
Headwinds
- Clinical data timelines are subject to study site activation progression and patient enrollment.
- IND clearance in additional autoimmune indications is required.
- Regulatory clearance is needed for ADI-270 Phase 1 study.
- Timelines are subject to study initiation progress.
- Future results may not be predictive of ongoing studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2023
+1.1%
Avg return
Earnings day
+1.2%
Avg return
5 days after
-5.0%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+29.7%
Q4 2021
Best reaction
-9.1%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +2.4% | -5.3% | +1.4% | |
| Q4 2025 | -3.2% | -1.6% | -4.0% | |
| Q3 2025 | -3.6% | -6.4% | -22.6% | |
| Q1 2025 | -6.9% | -7.5% | -7.9% | |
| Q4 2024 | -2.3% | +15.0% | -33.8% | |
| Q3 2024 | +1.5% | -3.8% | -19.8% | |
| Q2 2024 | +7.9% | +20.5% | +20.5% | |
| Q1 2024 | -2.8% | +11.1% | +0.7% | |
| Q4 2023 | +9.7% | +12.3% | +3.8% | |
| Q3 2023 | -4.9% | -10.3% | +4.9% | |
| Q2 2023 | +6.8% | -2.7% | -23.2% | |
| Q1 2023 | +4.1% | -4.5% | -14.9% | |
| Q4 2022 | -3.1% | -19.5% | -29.5% | |
| Q3 2022 | +1.9% | +11.0% | +3.8% | |
| Q2 2022 | -9.1% | -11.0% | -4.9% | |
| Q1 2022 | +8.6% | +13.1% | +9.6% | |
| Q4 2021 | +29.7% | +31.0% | +37.6% | |
| Q3 2021 | +3.2% | +0.8% | +49.7% | |
| Q2 2021 | +8.1% | -5.9% | +6.4% | |
| Q1 2021 | +1.5% | +7.7% | -22.5% | |
| Q4 2020 | -0.7% | +6.2% | -11.2% | |
| Q3 2020 | +5.9% | +9.2% | +22.3% | |
| Q2 2020 | +0.4% | +4.4% | -17.3% | |
| Q1 2020 | +9.1% | +10.3% | +24.6% | |
| Q4 2019 | -8.5% | -17.1% | -6.0% | |
| Q3 2019 | -5.3% | +6.7% | -85.2% | |
| Q2 2019 | -3.5% | -3.7% | -22.2% | |
| Q1 2019 | -4.6% | -7.3% | +1.3% | |
| Q4 2018 | -8.3% | -10.8% | -23.3% | |
| Q3 2018 | -5.8% | -5.2% | -2.7% | |
| Q2 2018 | +5.1% | -0.9% | +9.3% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro